Merck’s Jay Galeota Joins G&W Laboratories
Jay Galeota , Merck & Co’s former chief strategy and business development officer and president of emerging businesses, has been appointed president and chief operating officer of G&W Laboratories. He will take over the role from current president Kurt Orlofski, who will assume the newly created position of president of generics. Prior to joining G&W, Galeota spent 28 years at Merck, working both in the US and globally and helping to establish the Merck Global Health Fund and Innovative Venture Group, as well as leading the development and launching of Merck’s top-grossing products, Januvia and Janumet.
You may also be interested in...
The company said its own calculations suggested a mid-November readout could yield a positive result, keeping it on track for an EUA before the end of 2020.
New Chief Technology Officers named at Seres Therapeutics, ERYTech Pharma and Adicet Bio
Swiss biotech Molecular Partners will receive upfront payment of CHF60m, including equity.